Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.401
Neutral
RSI(14)
49.258
Neutral
STOCH(KDJ)(9,3,3)
30.665
Sell
ATR(14)
16.934
Low Volatility
CCI(14)
-144.735
Sell
Williams %R
73.424
Sell
TRIX(12,20)
0.287
Sell
StochRSI(14)
2.458
Oversold
Search
Regeneron Pharmaceuticals Inc
REGNAdd to Watchlist
651.870USD
+0.690+0.11%
Close 07-23 16:00（ET）Quotes delayed by 15 min
68.45BMarket Cap
15.34P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.11%
5 Days
-3.99%
1 Month
+5.48%
6 Months
-13.49%
Year to Date
-15.55%
1 Year
+13.89%
Key Figures
646.480Open
655.200High
1.00Volume
15.34P/E TTM
11.60P/E Dynamic
3.580Dividend TTM
0.00%Turnover Ratio
651.180Prev. Close
637.800Low
101.00Turnover
15.51P/E Static
2.18P/B
0.55%Div Yield TTM
11.40%ROA
821.11052wk High
-0.00Volume Ratio
4.41BNet Profit
105.00MShares
42.4810EPS TTM
0.26Beta
14.69%ROE
476.48752wk Low
2.67%Amplitude
81.43%Gross Margin
68.45BMarket Cap
2.56Reward/Risk
1.74%Risk Rate
TradingKey Stock Score of Regeneron Pharmaceuticals Inc
Currency: USD Updated: 2026-07-23Key Insights
Regeneron Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 7 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 816.02.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Regeneron Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
43°C
Very Low
Very High
Neutral
Regeneron Pharmaceuticals Inc Highlights
StrengthsRisks
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Undervalued
The company’s latest PE is 15.35, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 94.67M shares, decreasing 1.74% quarter-over-quarter.
Held by Mason Hawkins
Star Investor Mason Hawkins holds 160.58K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.16.
Analyst Rating
Based on
31
analysts
Buy
Current Rating
816.016
Target Price
+20.86%
Upside Space
Regeneron Pharmaceuticals Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
31
analysts
Buy
Current Rating
816.016
Target Price
+20.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Regeneron Pharmaceuticals Inc
REGN
31
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
665.424
Sell
MA10
665.424
Sell
MA20
654.925
Sell
MA50
641.676
Buy
MA100
694.571
Sell
MA200
705.783
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Regeneron Pharmaceuticals Inc Info
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Ticker SymbolREGN
CompanyRegeneron Pharmaceuticals Inc
CEOSchleifer (Leonard S)
Websitehttps://www.regeneron.com/
Shareholders
Related Instruments
+1.95%
+1.46%
-0.85%
+1.43%
+2.37%
+2.01%
+1.49%
+0.38%
0.00%
+0.71%
+1.27%
+0.15%
-0.94%
-0.03%
+1.31%
0.00%
+8.61%
-0.21%
+2.45%Popular Instruments
FAQs
What is the current price of Regeneron Pharmaceuticals Inc (REGN)?
The current price of Regeneron Pharmaceuticals Inc (REGN) is 651.87.
What is the symbol of Regeneron Pharmaceuticals Inc?
The ticker symbol of Regeneron Pharmaceuticals Inc is REGN.
What is the 52-week high of Regeneron Pharmaceuticals Inc?
The 52-week high of Regeneron Pharmaceuticals Inc is 821.11.
What is the 52-week low of Regeneron Pharmaceuticals Inc?
The 52-week low of Regeneron Pharmaceuticals Inc is 476.49.
What is the market capitalization of Regeneron Pharmaceuticals Inc?
The market capitalization of Regeneron Pharmaceuticals Inc is 68.45B.
Is Regeneron Pharmaceuticals Inc (REGN) currently rated as Buy, Hold, or Sell?
According to analysts, Regeneron Pharmaceuticals Inc (REGN) has an overall rating of Buy, with a price target of 816.02.
What is the Earnings Per Share (EPS TTM) of Regeneron Pharmaceuticals Inc (REGN)?
The Earnings Per Share (EPS TTM) of Regeneron Pharmaceuticals Inc (REGN) is 43.07.